Protego Biopharma

Protego Biopharma focuses on the discovery and development of first-in-class small molecule therapies designed to reprogram protein folding for the treatment of various systemic amyloid diseases, such as light chain (LC) amyloidosis. We also target other monogenic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, kidney disease, retinal disease, channelopathies, and various degenerative conditions. Our approach builds on the previously validated pharmacological chaperone method represented by tafamidis, which was discovered and developed by our co-founders, Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis.